“For RPT193, we successfully completed the healthy volunteer portion of the study. Our primary objective is patient safety and we will adapt to local circumstances as needed. Because of the life-threatening nature of the cancers, we are working site by site to ensure that patients receive treatment and follow up as close to protocol-specified intervals as feasible.
Rapt 1400 reviews trial#
Wong continued, “For our ongoing Phase 1/2 study of FLX475, we continue to enroll and treat patients with multiple types of advanced cancer, though we are monitoring the impact of COVID-19 on our clinical trial sites both within and outside of the U.S. “In addition, we partnered with Hanmi for FLX475 in Asia, a region with a high prevalence of ‘charged’ tumors, and we strengthened our balance sheet substantially with our follow-on offering in February 2020.”ĭr. “2019 was an especially productive year for RAPT with the completion of our initial public offering and the generation of encouraging early clinical data for our two lead immunology-based programs: FLX475 for the treatment of multiple cancers and RPT193 for the treatment of atopic dermatitis and other allergic inflammatory diseases,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.
Rapt 1400 reviews update#
( RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the fourth quarter ended Decemand provided an update on recent operational and business progress. SOUTH SAN FRANCISCO, Calif., Ma(GLOBE NEWSWIRE) - RAPT Therapeutics, Inc. Company bolsters cash by $116 million with public offerings in late 2019 and early 2020
0 kommentar(er)
